APA (7th ed.) Citation

GL, B., A, C., DL, C., M, T., JGJV, A., F, B., . . . A, A. (2021). The lung immuno-oncology prognostic score (LIPS-3): A prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer. ESMO open, 6(2), 100078. https://doi.org/10.1016/j.esmoop.2021.100078

Chicago Style (17th ed.) Citation

GL, Banna, et al. "The Lung Immuno-oncology Prognostic Score (LIPS-3): A Prognostic Classification of Patients Receiving First-line Pembrolizumab for PD-L1 ≥ 50% Advanced Non-small-cell Lung Cancer." ESMO Open 6, no. 2 (2021): 100078. https://doi.org/10.1016/j.esmoop.2021.100078.

MLA (9th ed.) Citation

GL, Banna, et al. "The Lung Immuno-oncology Prognostic Score (LIPS-3): A Prognostic Classification of Patients Receiving First-line Pembrolizumab for PD-L1 ≥ 50% Advanced Non-small-cell Lung Cancer." ESMO Open, vol. 6, no. 2, 2021, p. 100078, https://doi.org/10.1016/j.esmoop.2021.100078.